Tech giants are moving AI pharmaceuticals from model contests to closed loop contests. Recently, Anthropic, ByteDance, etc. have increased the field of AI pharmaceuticals. For example, Anthropic has built a wet laboratory in the San Francisco Bay Area of the United States; Anew Labs, an AI pharmaceutical company under ByteDance, completed the first round of external financing as an independent company, with a scale of US$290 million; Lilly Tunelab, an AI pharmaceutical platform under Lilly TuneLab joined hands with Kingsley, Twist, and Ginkgo to improve the AI pharmacogenicity prediction and verification chain... The reporter interviewed a number of AI pharmaceutical listed company executives and industry insiders to learn that the competitive focus in the AI pharmaceutical field is shifting to “who can build a systemic infrastructure for the industry” and take the lead Complete closed loop of “data - model - experiment - data again”. Along with this, the division of labor in the industry is moving from fighting alone to ecological competition.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.